In bladder cancer, METTL3 deletion resulted in reduced m6A abundance in specific regions of tyrosine kinase endothelial (TEK) and VEGF-A mRNA and decreased levels of TEK and VEGF-A mRNA and protein [57]. Here, METTL3 is linked to urinary bladder cancer.